In the News
CRO’s FSP model proves to be the right choice
Gary Barker, Denise Moody, April Pierce and Magda Santos explain how PPD used an FSP model to help build a solid, long-term partnership with a top 25 pharmaceutical organization.
CRO Industry Update: Big Data Drives Drug Development Efforts
PPD’s David Johnston and Evidera’s Eric Faulkner comment on the changing clinical development landscape.
Today’s Feasibility Challenge: Harnessing Data to Deliver Patients into Clinical Trials
Gaurav Bhatnagar discusses how data-driven feasibility assessment is at the heart of the emerging evidence-based clinical trial process.
FDA Regenerative Medicine Policy Framework and Advanced Therapy Designation
Richard Dennett and Kirsten Messmer provide an overview of the policy framework established by the U.S. Food and Drug Administration for the regulation of regenerative medicine and advanced therapies.
PPD becomes first CRO partner for MIT’s initiative
Initiative provides its members an environment, programs and practices for open, non-competitive collaboration.
PPD joins MIT think tank focused on real-world evidence
Relationship to serve as an extension of company’s ongoing innovation efforts in the areas of real-world research, patient-centered research, pragmatic trials and platform studies.
PPD, Evidera join MIT ‘think and do’ tank as a strategic partner
PPD becomes the first contract research organization to join the MIT Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS).
Improvements to Study Startup Underway
Gaurav Bhatnagar comments on how technology and data-driven approaches will be key to “bending the cost and time curve” of drug development.
Patient-Centered Apps
Acurian’s Scott Connor notes that the most important aspect when designing any app is to create something that has a singular purpose.
